| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/31/2012 | CA2550373C Anti-hypercholesterolemic compounds |
| 01/31/2012 | CA2529649C Substituted spirobenzazepines |
| 01/31/2012 | CA2516698C Novel transcriptional factor, process for producing the same and use thereof |
| 01/31/2012 | CA2463989C Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
| 01/26/2012 | WO2012012477A1 Substituted 3-phenyl-1,2,4-oxadiazole compounds |
| 01/26/2012 | WO2012012370A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | WO2012012347A2 Methods of intravenous administration of glyburide and other drugs |
| 01/26/2012 | WO2012012278A2 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | WO2012011882A1 A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases |
| 01/26/2012 | WO2012011592A1 Heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011591A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011572A1 Therapeutic agent for diastolic heart failure |
| 01/26/2012 | WO2012011125A1 Agonists of gpr40 |
| 01/26/2012 | WO2012010802A1 Process for preparing benzofuran derivatives substituted at position 5 |
| 01/26/2012 | WO2012010606A1 Hexacyclic polyketides as kinase inhibitors |
| 01/26/2012 | WO2012010578A1 Substituted methyl-pyrimidin-5-yl carbamates and use thereof |
| 01/26/2012 | WO2012010577A1 Substituted oxazolidinones and oxazinanones and use thereof |
| 01/26/2012 | WO2012010576A1 Carbamate-substituted diaminopyrimidines and use thereof |
| 01/26/2012 | WO2012010571A1 Dronedarone for the prevention of cardiovascular hospitalization or of mortality in patients with lone atrial fibrillation |
| 01/26/2012 | WO2011150457A3 Haematopoietic-prostaglandin d2 synthase inhibitors |
| 01/26/2012 | WO2011147028A3 Apple skin extracts for treating cardiovascular disease |
| 01/26/2012 | WO2011147026A3 A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| 01/26/2012 | WO2011118928A3 Pharmaceutical composition for preventing or treating heart failure and method for screening agent for preventing or treating heart failure |
| 01/26/2012 | WO2011106226A3 Prolylhydroxylase inhibitors and methods of use |
| 01/26/2012 | US20120022500 Compositions and Methods for Induced Brown Fat Differentiation |
| 01/26/2012 | US20120022268 New Salt Hydrates |
| 01/26/2012 | US20120022236 Recombinant Anti-VLA4 Antibody Molecules |
| 01/26/2012 | US20120022166 Methods for Modulating Macrophage Proliferation Using Polyamine Analogs |
| 01/26/2012 | US20120022161 Acetycysteine compositions and methods of use thereof |
| 01/26/2012 | US20120022159 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof |
| 01/26/2012 | US20120022155 Use of aminaphtone for the preparation of a medicament for treating arteriopathies |
| 01/26/2012 | US20120022147 2, 6 xylidine derivatives for the treatment of pain |
| 01/26/2012 | US20120022139 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration |
| 01/26/2012 | US20120022138 Means for inhibiting the expression of ang2 |
| 01/26/2012 | US20120022133 Antisense modulation of cholesteryl ester transfer protein expression |
| 01/26/2012 | US20120022119 Heterocyclic antagonists of prostaglandin d2 receptors |
| 01/26/2012 | US20120022116 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | US20120022109 Oxadiazole derivatives |
| 01/26/2012 | US20120022100 Organic compounds |
| 01/26/2012 | US20120022092 Protein kinase c inhibitors and uses thereof |
| 01/26/2012 | US20120022087 Amorphous ambrisentan |
| 01/26/2012 | US20120022084 Substituted 5-fluoro-1H-pyrazolopyridines and their use |
| 01/26/2012 | US20120022083 Small molecule modulators of cell adhesion |
| 01/26/2012 | US20120022080 Plasminogen Activator Inhibitor-1 Inhibitor |
| 01/26/2012 | US20120022079 Method For Producing Preparations Of Substances Poorly Soluble In Water |
| 01/26/2012 | US20120022076 Derivatives of n-(arylamino)sulfonamides as inhibitors of mek |
| 01/26/2012 | US20120022072 Pterin analogs |
| 01/26/2012 | US20120022069 Acrylamide compounds and the use thereof |
| 01/26/2012 | US20120022068 NOVEL HETEROCYCLIC NF-kB INHIBITORS |
| 01/26/2012 | US20120022060 Tricyclic Azaindoles |
| 01/26/2012 | US20120022058 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| 01/26/2012 | US20120022035 Polymorphic and Amorphous Salt Forms of Squalamine Dilactate |
| 01/26/2012 | US20120022033 Methods for decreasing cardiovascular risk in postmenopausal women |
| 01/26/2012 | US20120022030 Tetracyclic Lactame Derivatives |
| 01/26/2012 | US20120022010 Use of flavonoids to increase the bioavailability of hesperetin |
| 01/26/2012 | US20120022007 Method and composition for modulating canonical wnt pathway using folate and inositol |
| 01/26/2012 | US20120022001 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle |
| 01/26/2012 | US20120021990 Peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
| 01/26/2012 | US20120021982 Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction |
| 01/26/2012 | US20120021980 Compositions for drug administration |
| 01/26/2012 | US20120021976 Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| 01/26/2012 | US20120021974 Novel inhibitor of angiogenesis |
| 01/26/2012 | US20120021973 Peptides for Treatment of Obesity |
| 01/26/2012 | US20120021972 Peptidomimetics with glucagon antagonistic and glp 1 agonistic activities |
| 01/26/2012 | US20120021971 Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof |
| 01/26/2012 | US20120021470 Chimeric PUFA Polyketide Synthase Systems and Uses Thereof |
| 01/26/2012 | US20120021080 Production and Extraction of Procyanidins from Plant Cell Cultures |
| 01/26/2012 | US20120021079 Garcinia Mangostana L. and Iridoid Based Formulations |
| 01/26/2012 | US20120021053 Controlled release and taste-masking oral pharmaceutical composition |
| 01/26/2012 | US20120021048 Combination Dosage Compositions Comprising a Cholesterol-Lowering Agent, a Renin-Angiotensin System Inhibitor, an Antioxidant Agent and an Antiplatelet Agent for Treatment and Prevention of Cardiovascular Disease |
| 01/26/2012 | US20120021044 Novel Cationic Lipid, A Preparation Method of the Same and A Delivery System Comprising the Same |
| 01/26/2012 | US20120021021 Method for preparing pharmaceutical compositions comprising fine particles of active substance |
| 01/26/2012 | US20120021019 Cardiac stem cell populations for repair of cardiac tissue |
| 01/26/2012 | US20120021017 N-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120021016 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120021011 Anti-inflammatory pharmaceutical composition comprising extracts from broussonetia papyrifera and lonicera japonica |
| 01/26/2012 | US20120021010 Antiplatelet agent and methods of using the same |
| 01/26/2012 | US20120020982 Formulations and treatments for trichology |
| 01/26/2012 | US20120020976 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 01/26/2012 | US20120020975 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 01/26/2012 | US20120020956 Activation of sodium potassium atpase |
| 01/26/2012 | US20120020951 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | US20120020948 Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke |
| 01/26/2012 | US20120020936 Treatment of neurodegenerative disease using placental stem cells |
| 01/26/2012 | US20120020935 Cardiac stem cells and methods for isolation of same |
| 01/26/2012 | US20120020927 Bacterial Strains Having an Outstanding Ability to Produce Menaquinone |
| 01/26/2012 | US20120020925 Therapeutic Use of Specialized Endothelial Progenitor Cells |
| 01/26/2012 | US20120020911 Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| 01/26/2012 | US20120020885 MHC-Less cells |
| 01/26/2012 | US20120020882 Peptide-based compounds |
| 01/26/2012 | US20120020876 Hedgehog pathway inhibitors |
| 01/26/2012 | DE102010031667A1 Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung Substituted methyl-pyrimidin-5-ylcarbamate and their use |
| 01/26/2012 | DE102010031666A1 Carbamat-substituierte Diaminopyrimidine und ihre Verwendung Carbamate substituted diaminopyrimidines and their use |
| 01/26/2012 | DE102010031665A1 Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung Substituted oxazolidinones and Oxazinanone and their use |
| 01/26/2012 | DE102010027595A1 Clinical application of adenosine derivative, preferably (dihydroxyphenyl)ethyl-amino-purin-9-yl-(hydroxymethyl)oxolane-diol, for reducing body temperature during impending ischemia of brain vessels, which occur during heart attacks |
| 01/26/2012 | CA2806258A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | CA2806069A1 Methods of intravenous administration of glyburide and other drugs |
| 01/26/2012 | CA2805868A1 Process for preparing benzofuran derivatives substituted at position 5 |
| 01/26/2012 | CA2805808A1 Agonists of gpr40 |
| 01/26/2012 | CA2805745A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |